Clinical trial · Observational
Metastatic Colorectal Cancer. Real-World Data Analysis.
The Treatment Choices, Duration and Outcomes in Patients With Ras Wild Type (RAS WT) Metastatic Colorectal Cancer (mCRC). Retrospective, Multi-Center, Real-World Data Analysis
NCT04757311CI-TRIAL-00054698RWD-mCRC-001completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The Treatment Choices, Duration and Outcomes in Patients with Ras Wild Type (RAS WT) Metastatic Colorectal Cancer (mCRC). Retrospective, Multi-Center, Real-World Data Analysis
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Metastatic Colorectal Cancer Patients
- description
- All RAS wild type metastatic colorectal cancer patients
Primary outcomes (2)
- measure
- Percentage of use anti-EGFR agents
- timeFrame
- throughout of treatment, 3 years
- description
- The anti-EGFR agent selection
- measure
- Progression Free Survival (PFS)
- timeFrame
- 3 years treatment
- description
- PFS three years after initiation of treatment with anti-EGFR agents
Secondary outcomes (1)
- measure
- Advers events
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients who have been histologically diagnosed with mCRC 2. Patients over the age of 18 3. Patients receiving at least a cycle systemic treatment for metastatic disease 4. RAS wild type patients 5. Patients who has demographic, histopathological and clinical information Exclusion Criteria: 1. Patients diagnosed as mCRC but only referred to BSC 2. Patients with RAS mutation 3. Patients who were included in any clinical trial except standard treatments during their treatment
References
Publications (0)
Data not yet available
No reference posted for this study.